The Warfarin/Aspirin Study in Heart failure
| ISRCTN | ISRCTN76146656 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN76146656 |
| Protocol serial number | D15 |
| Sponsor | Record Provided by the NHS R&D 'Time-Limited' National Programme Register - Department of Health (UK) |
| Funder | NHS Cardiovascular Disease and Stroke National Research and Development Programme (UK) |
- Submission date
- 23/01/2004
- Registration date
- 23/01/2004
- Last edited
- 22/02/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof John Cleland
Scientific
Scientific
Castle Hill Hospital
University of Hull
Cottingham
Kingston upon Hull
HU16 5UQ
United Kingdom
| Phone | +44 (0)1482 624 083/084 |
|---|---|
| J.G.Cleland@hull.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | What is the most cost effective anti-thrombotic strategy to reduce mortality in heart failure? The WASH Study |
| Study acronym | WASH Study |
| Study objectives | Heart failure is common and causes appreciable morbidity and mortality. It is associated with recurrent myocardial infarcts, strokes, and other thrombo-embolic events. For these reasons anti-thrombotic therapy using aspirin or warfarin is seen as normal clinical practice. However aspirin has a number of side-effects, and warfarin requires regular blood tests, increasing its cost and inconvenience for patients. Thus using these agents should be justified by clinical benefit. The aim of this study was to see if it would be possible to organise a trial of aspirin, warfarin, and no anti-thrombotic treatment. |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Heart disease |
| Intervention | 1. Aspirin 2. Wafarin 3. No anti-thrombotic treatment |
| Intervention type | Other |
| Primary outcome measure(s) |
1. Deaths |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 30/09/1998 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target sample size at registration | 279 |
| Key inclusion criteria | Patients were being treated for heart failure, and had evidence of ventricular dysfunction to a defined level on echocardiography. |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 01/11/1995 |
| Date of final enrolment | 30/09/1998 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Castle Hill Hospital
Kingston upon Hull
HU16 5UQ
United Kingdom
HU16 5UQ
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | Results | 01/07/2004 | Yes | No |
